16929-05-8

Basic information

• Product Name: 1-(3,4-METHYLENEDIOXYPHENYL)BUTANE
• Synonyms: TIMTEC-BB SBB008465;1-(3,4-METHYLENEDIOXYPHENYL)BUTANE;5-BUTYL-1,3-BENZODIOXOLE;4-BUTYL-1,2-METHYLENEDIOXYBENZENE
• CAS NO: 16929-05-8
• Molecular Formula: C₁₁H₁₄O₂
• Molecular Weight: 178.23
• Mol File: 16929-05-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 251.4 °C at 760 mmHg
• Flash Point: 111 °C
• Appearance: /
• Density: 1.07 g/cm³
• Vapor Pressure: 0.0326mmHg at 25°C
• Refractive Index: 1.527
• CAS DataBase Reference: 1-(3,4-METHYLENEDIOXYPHENYL)BUTANE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,4-METHYLENEDIOXYPHENYL)BUTANE(16929-05-8)
• EPA Substance Registry System: 1-(3,4-METHYLENEDIOXYPHENYL)BUTANE(16929-05-8)

Safety Data

• Hazardous Substances Data: 16929-05-8(Hazardous Substances Data)

Usage

General Description

1-(3,4-methylenedioxyphenyl)butane, also known as MDB, is a synthetic compound with a chemical structure that includes a benzene ring with a methylenedioxy group attached to a butane chain. It is classified as a psychoactive substance and is commonly used as a recreational drug known by the street name "MDBD". MDB is a derivative of the phenethylamine class of compounds and is structurally related to amphetamine and MDMA (ecstasy). It is known for its stimulant and euphoric effects and is often used for its psychoactive properties. However, it is also associated with significant health risks and potential for abuse. It is a controlled substance in many countries due to its psychoactive and potentially harmful effects.

InChI:InChI=1/C11H14O2/c1-2-3-4-9-5-6-10-11(7-9)13-8-12-10/h5-7H,2-4,8H2,1H3

Upstream product

• 274-09-9 Methylenedioxybenzene 
• 1220985-67-0 N'-(1-(benzo[d][1,3]dioxol-5-yl)butylidene)-4-methylbenzenesulfonohydrazide 
• 63740-97-6 1-(2H-benzo[3,4-d]1,3-dioxolen-5-yl)butan-1-one 
• 109-72-8 n-butyllithium 
• 2635-13-4 1,2-(methylenedioxy)-4-bromobenzene 
• 120-57-0 piperonal 
• 106-89-8 epichlorohydrin 

Relevant articles and documents

Differential induction of cytochrome P450 gene expression by 4n-alkyl-methylenedioxybenzenes in primary rat hepatocyte cultures.

A well-characterized primary rat hepatocyte culture system was used to examine induction patterns of cytochrome 450 gene expression by a series of 4-n-alkyl-methylenedioxybenzene (MDBs) derivatives. Hepatocytes were treated for 24, 48, or 72 hours with 0-500 microM of the MDB compounds, and total cellular RNA and protein from each treatment was evaluated by hybridization and immunochemical techniques. Exposure to MDB congeners possessing increasing 4-n-alkyl side-chain length (C0-C8) resulted in dose- and structure-dependent activation of CYP2B1, 2B2, 3A1, 1A1, and 1A2 gene expression. At equivalent 100 microM concentrations, the C6 and C8 MDB congeners were more effective than the prototypical inducer phenobarbital (PB) with respect to induction potency of CYP2B1, CYP2B2, and CYP3A1 gene expression. In contrast to PB, longer side-chain-substituted MDBs effectively induced CYP1A1 and CYP1A2 gene expression, in addition to the CYP2B and CYP3A genes. At equivalent molar concentrations, the catechol derivative of C6-MDB was ineffective in its ability to induce CYP gene expression, indicating the importance of the intact methylenedioxy bridge in the induction mechanism. Levels of MDB-inducible CYP2B1 and CYP2B2 mRNA were highly correlated with CYP2B1/2 apoprotein levels, ascertained by immunoblot analysis of cultured hepatocyte S9 fractions. Compared with results from previous in vivo analysis (12), the current data indicate that pharmacodynamic factors may influence MDB induction profiles and that differences in MDB effects on CYP gene expression result depending on distinct structure-activity relationships.

A PROCESS FOR PREPARATION OF ALKENYL AND ALKYL DERIVATIVES OF ALKYLENEDIOXYBENZENE

The present disclosure generally relates to the method of preparation of compounds of Formula IV. An aspect of the present disclosure relates to a process for preparation of compound of Formula IV, said process comprising the step of reacting an alkylenedioxybenzene compound of Formula II with an acyl halide of Formula III in presence of a solvent, characterized in that the step of reacting the alkylenedioxybenzene compound of Formula II with the acyl halide of Formula III is effected in the presence of an amphoteric oxide so as to in-situ quench the compound of formula H-X formed during the course of the reaction, thereby substantially eliminating degradation of the compounds of Formula IV and Formula II.

N-Tosylhydrazine-mediated deoxygenative hydrogenation of aldehydes and ketones catalyzed by Pd/C

A mild and efficient method for the deoxygenative hydrogenation of aldehydes and ketones has been developed. The reaction is mediated by N-tosylhydrazine with H2 (1 atm) as the reductant and 10% Pd/C as the catalyst.